Tumor Budding and Stromal Reaction in Colorectal Adenocarcinoma: A Histomorphological Review of Prognostic Significance
Keywords:
colorectal adenocarcinoma, tumor budding, stromal reaction, tumor stroma ratio, desmoplastic reaction, prognostic markerAbstract
Objective: This review aims to critically evaluate the prognostic significance of tumor budding and stromal reaction in colorectal adenocarcinoma and to examine their incremental value in risk stratification beyond conventional TNM staging.
Methods: A structured literature review was conducted using PubMed, ScienceDirect, SpringerLink, and Google Scholar. Searches employed Boolean operators (“AND”, “OR”) with the terms “tumor budding,” “stromal reaction,” “desmoplastic reaction,” “tumor stroma ratio,” and “colorectal adenocarcinoma.” Peer-reviewed cohort studies, retrospective analyses, and systematic reviews published between 2015 and 2025 were included if they evaluated standardized histopathological assessment and reported survival or recurrence outcomes. Studies lacking prognostic endpoints or reproducible scoring criteria were excluded.
Results: The majority of contemporary studies demonstrate that high grade tumor budding defined as isolated single cells or clusters of up to four tumor cells at the invasive front is independently associated with lymphovascular invasion, lymph node metastasis, distant dissemination, and reduced disease free and overall survival. Standardized evaluation, particularly following consensus based criteria, improves interobserver reproducibility and prognostic consistency. Stromal reaction, especially desmoplastic and stroma rich patterns reflected in a low tumor stroma ratio, has also been shown to independently predict unfavorable outcomes and increased recurrence risk. Emerging evidence suggests that the combined assessment of tumor budding and stromal composition provides superior prognostic discrimination compared with histological grade alone, particularly in stage II colorectal adenocarcinoma where therapeutic decision making remains challenging.
Conclusion: Tumor budding and stromal reaction are biologically meaningful and clinically applicable histomorphological markers that reflect tumor microenvironment interaction and invasive potential. Their integration into routine pathological reporting may enhance prognostic precision and support more individualized adjuvant treatment strategies, especially in intermediate risk disease.
References
1. Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA: A Cancer Journal for Clinicians. 2021;71(3):209–249. https://doi.org/10.3322/caac.21660
2. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Colon cancer (Version 2023). NCCN; 2023.
3. Lugli A, Kirsch R, Ajioka Y, Bosman F, Cathomas G, Dawson H, et al. Recommendations for reporting tumor budding in colorectal cancer based on the International Tumor Budding Consensus Conference (ITBCC) 2016. Modern Pathology. 2017;30(9):1299–1311. https://doi.org/10.1038/modpathol.2017.46
4. Almangush A, Mäkitie AA, Hagström J. Tumour budding in colorectal cancer: State of the art and future perspectives. Cancers. 2023;15(2):386. https://doi.org/10.3390/cancers15020386
5. Zhang L, Wang H, Li C, et al. Tumor–stroma ratio as a prognostic factor in colorectal cancer: Updated evidence from systematic review and meta-analysis. Frontiers in Oncology. 2022;12:857880. https://doi.org/10.3389/fonc.2022.857880
6. Bokhorst JM, Blank A, Lugli A, Zlobec I. Tumor budding in colorectal cancer: Clinical implications and future perspectives. Nature Reviews Clinical Oncology. 2020;17(4):197–210. https://doi.org/10.1038/s41571-019-0282-4
7. van Pelt GW, Sandberg TP, Morreau H, Gelderblom H, van Krieken JHJM, Tollenaar RAEM. The tumour–stroma ratio in colon cancer: Prognostic value and role in clinical decision-making. Cancers. 2021;13(9):2053. https://doi.org/10.3390/cancers13092053
8. Huijbers A, Tollenaar RAEM, Vahrmeijer AL, et al. The proportion of tumour stroma as a strong prognosticator for stage II and III colon cancer patients. Gut. 2021;70(7):1346–1355. https://doi.org/10.1136/gutjnl-2020-322345
9. Kemi N, Eskuri M, Herva A, et al. Tumour budding and desmoplastic reaction in colorectal cancer: Associations with survival and tumour microenvironment. Histopathology. 2022;81(3):412–423. https://doi.org/10.1111/his.14673
10. Isella C, Terrasi A, Bellomo SE, et al. Stromal contribution to the colorectal cancer transcriptome and clinical outcome. Nature Communications. 2022;13:857. https://doi.org/10.1038/s41467-022-28523-7
